PPARα/γ双重激动剂治疗非酒精性脂肪性肝病

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)是全球最多见的慢性肝病,与肝硬化、肝细胞癌的高发及其相关病死率增加密切相关。然而至今尚无治疗NAFLD的特效药物,过氧化物酶体增殖物激活受体(PPAR)及其配体家族参与调节机体的脂质、葡萄糖和能量稳态,对NAFLD患者的代谢功能障碍及其相关肝脏炎症和纤维化具有潜在治疗作用。本文阐述了PPAR-α/γ双重激动剂Saroglitazar治疗NAFLD的最新研究结果及机制。

杨菁, 范建高. PPARα/γ双重激动剂治疗非酒精性脂肪性肝病[J]. 肝脏, 2021, 26(12): 1311-1312.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 实用肝脏病杂志,2018, 21:177-186.
[2] Fan JG, Kim SU, Wong Vincent WS. New Trends on Obesity and NAFLD in Asia. J Hepatol, 2017,67:862-873.
[3] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67:328-357.
[4] Francque S, Szabo G, Abdelmalek MF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol,2021,18:24–39.
[5] Lic P, Siersb?k M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol,2012,23:631-639.
[6] Wang Y, Nakajima T, Gonzalez FJ, et al. PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-Null mice. Int J Mol Sci,2020,21: 2061.
[7] Francque S, Verrijken A, Caron S, et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J. Hepatol,2015,63:164-173.
[8] Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and-δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology,2016,150:1147-1159.
[9] Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med,2016,165:305-315.
[10] Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology,2021,74(4):1809-1824.
[11] Jani RH, Kansagra K, Jain MR, et al. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig,2013,33: 809-816.
[12] Jain MR, Giri SR, Trivedi C, et al. Saroglitazar, a novel PPARalpha/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect,2015,3:e00136.
[13] Jain MR, Giri SR, Bhoi B, et al. Dual PPARalpha/gamma agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int,2018,38: 1084-1094.
[14] Kumar DP, Caffrey R, Marioneaux J, et al. The PPARα/γagonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci Rep,2020,10: 9330.
[15] Maximos M, Bril F, Portillo Sanchez P, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology,2015,61:153-160.
[16] Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep,2019,1:312-328.
[17] Sven MF, Pierre B, Manal FA, et al. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. Contemp Clin Trials,2020,98:106170.
[18] Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017,66:1138-1153.
[19] Gawrieh S, Chalasani N. Emerging treatments for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis,2018,22:189-199.
[20] Spence JD, Viscoli CM, Inzucchi SE, et al. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurol,2019,76:526-535.